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Peptaibiotics are a group of membrane active peptides of fungal
origin. They typically contain α-aminoisobutyric acid (Aib; 1-letter
code, U) and other non-coded residues (Toniolo and Brückner,
2009; Neumann et al., 2015; Benedett et al., 1982) [1–3] stabilizing
their helical structure. Peptaibols are peptaibiotics carrying a 1, 2-
aminoalcohol at the C-terminus. When a fatty acid chain (of 8–10
carbon atoms) is present at their N-terminus, they are called
lipopeptaibols (Toniolo et al., 2001; Degenkolb et al., 2003) [4,5].
We found (Tavano et al., 2015) [6] that the lipopeptaibol trichogin
displays no antibacterial effects up to 64 mM, against both Gram
and Gramþ bacteria, but kills tumor and healthy human cells via a
mechanism requiring both the C-terminal primary alcohol group
and the N-terminal n-octanoyl moiety, with EC50s around 4–5 mM.
However, the substitution of single Gly residues with Lys strongly
improves anti-Gramþ activity (Tavano et al., 2015; De Zotti, Biondi,
Park et al., 2012; De Zotti, Biondi, Peggion et al., 2012) [6–8]. To
further characterize the activity of trichogin analogs as antibiotics
and cytotoxic agents, we here manipulated the peptide helix
amphipathicity by means of two different substitutions: (i) Aib to
Leu (De Zotti et al., 2012) [7] or (ii) multiple Gly to Lys changes
(Tavano et al., 2015; De Zotti, Biondi, Park et al., 2012; De
Zotti, Biondi, Peggion, Formaggio et al., 2012; De Zotti, Biondi,
Peggion, De Poli et al., 2012) [6–9]. The antibacterial activity
against four commensal or opportunistic bacterial species and the
cytotoxicity against a panel of 9 healthy and tumor-derivedvier Inc. This is an open access article under the CC BY license
apini).
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R. Tavano et al. / Data in Brief 6 (2016) 359–367360eukaryotic cell types (including erythrocytes) are reported as MIC
and EC50 (MTS - [3-(4, 5-dimethylthiazol-2-yl)-5-(3-carbox-
ymethoxyphenyl)-2-(4-sulfophenyl)]-2H-tetrazolium- reduction
and LDH - lactate dehydrogenase - release assay).
& 2015 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations TableSubject area Chemistry, Biologyore speciﬁc sub-
ject areaPeptaibolsype of data Table, text ﬁle, graph, ﬁgures
ow data was
acquiredHPLC, mass spectrometry, FACS, spectroﬂuorimetryata format Analyzed
xperimental
factorsDifferent kind of bacterial or eukaryotic cells were treated with different con-
centrations of peptides for 24 hxperimental
featuresAfter incubation with peptides, cell viability (MTS assay), type of death
(Annexin-propidium iodide assay) or ﬂuorescence associated to the cells (FACS
analysis) were assessedata source
locationUniversity of Padova, Italyata accessibility The data are supplied with this articleD
Value of the data
 The need to ﬁnd new antibacterial agents able to overcome antibiotic resistance and, at the same
time, the expectation of having new effective antitumor drugs may beneﬁt from the accurate
quantiﬁcation of the antimicrobial and cytotoxic efﬁcacy and selectivity of peptaibols.
 We here report quantitative data from which it is possible to compare the antibiotic activity and
the cytocidal efﬁcacy of several analogs of trichogin GA IV.
 The data reported here may be useful since they provide a base for possible further design and
reﬁnement of either anti-microbial or anti-tumor activity of trichogin-derived peptides.1. Data
1.1. Antibacterial activity of trichogin and its analogs
As previously observed [7], analogs L1 and L1,8 (Table 2; throughout text, the 1-letter code for amino
acids was used) showed a moderately improved anti Staphylococcus aureus (S. aureus) activity (MIC after 24
from 464 μM to 32 μM), whilst L4, known to have a destabilized helix [7], showed no such increase.
Introduction of one, two or three K residues in the sequence (Table 1) induced a strong MIC (24 h) decrease
against the Gramþ bacteria tested (2–5 μM) and the Gram Escherichia coli (E. coli) (8–16 μM) (Table 2).
Anti-Gram Pseudomonas aeruginosa (P. aeruginosa) activity was also improved in di- or tri-K containing
analogs (MIC, 12–16 μM). To further improve the antibacterial activity of the K-containing analogs we
introduced an additional U residue at position 6, to stabilize the helix (K5U6, K2K5K9U6). In addition, we
replaced U at position 1 with L (L1K2, L1K9) as this substitution was shown to improve the activity of
Table 2
MICs (μM7SE; NZ4; peptides dose range: 0–64 mM) after 24 h against two Gramþ and two Gram bacterial strains (§
indicates data from [6] for comparison).
Compound S. aureus S. epidermis P. aeruginosa E. coli
GA IV (§) 464 464 464 464
L1 3270 464 464 464
L4 464 464 464 464
L1L8 3270 464 464 464
K2 (§) 371.4 4.372 464 24717.1
K5 170 270 464 872
K6 (§) 371.7 470 464 1670
K9 (§) 5.372.1 4.771.6 57716 32717.5
K2K5 3.371.3 572.4 1675 13.773.9
K2K6 2.871.1 3.272.6 17.678.8 12.674.3
K5K6 470 471 1670 1670
K2K5K9 4.371.8 470.9 13.374.1 14.978.6
K5U6 3.872.4 2.470.9 464 464
K2K5K9U6 470 870 870 870
L1K2 4.671.5 4.771.6 464 22.978.6
L1K9 4.771.6 4.671.5 464 41.1715.6
Table 1
Trichogin and its analogs used in this work.
Sequence Name Ref. [MþH]þcalcd [MþH]þ found Rt (min)n
Oc-UGLUGGLUGILol GA IV [1] – – –
Oc-LGLUGGLUGILol L1 [4] – – –
Oc-UGLLGGLUGILol L4 [4] – – –
Oc-LGLUGGLLGILol L1L8 [1–4] – – –
Oc-LGLLGGLLGILol L1L4L8 This work 1150.81 1150.80 19.23a
Oc-UGLUK(HCl)GLUGILol K5 [1] – – –
Oc-UK(HCl)LUK(HCl)GLUGILol K2K5 This work 1208.86 1208.91 12.93b
Oc-UK(HCl)LUGK(HCl)LUGILol K2K6 This work 1208.86 1208.85 24.34c
Oc-UGLUK(HCl)K(HCl)LUGILol K5K6 [1] – – –
Oc-UK(HCl)LUK(HCl)GLUK(HCl)ILol K2K5K9 This work 1279.94 1280.02 11.36b
Oc-UGLUK(HCl)ULUGILol K5U6 This work 1165.82 1165.82 20.25d
Oc-UK(HCl)LUK(HCl)ULUK(HCl)ILol K2K5K9U6 [1] – – –
Oc-LK(HCl)LUGGLUGILol L1K2 This work 1165.82 1165.79 22.19e
Oc-LGLUGGLUK(HCl)ILol L1K9 This work 1165.82 1165.88 13.24f
Oc, octanoyl; U, Aib; Lol, leucinol.
n HPLC retention time. Elution conditions: column, if not otherwise speciﬁed, Phenomenex Jupiter 300 Å, 5m, C18; ﬂow,
1 ml/min; eluent A: 9:1 H2O/CH3CNþ0.05% TFA; eluent B: 9:1 CH3CN/H2Oþ0.05% TFA.
a Gradients used: 70–100%B in 15 min (column: Vydac 300 Å, 5m, C4).
b Gradients used: 50–80%B in 20 min.
c Gradients used: 10–90%B in 30 min.
d Gradients used: 60–100%B in 22 min.
e Gradients used: 30–100%B in 30 min.
f Gradients used: 60–80%B in 20 min.
R. Tavano et al. / Data in Brief 6 (2016) 359–367 361trichogin against S. aureus [7]. However, these modiﬁcations failed to increase the antibacterial activity
(Table 2).
1.2. Cytotoxic effects of trichogin analogs with multiple G to K substitutions
To monitor the possible differential cytocidal effect of trichogin and its analogs on human cells
(healthy and cancer cells, non-leukocytes and leukocytes), we incubated the peptides with (i) primary
R. Tavano et al. / Data in Brief 6 (2016) 359–367362human leukocytes (lymphocytes, PMNs and monocytes), freshly isolated from blood of healthy
donors (ii) the monocytes-like HL60 cell line from human myeloid leukemia, and (iii) three tumor-
derived non-leukocyte cells lines: HeLa (human ovary sarcoma), A431 (human epidermoid carci-
noma) and A549 (human lung carcinoma) and the in vitro stabilized line CCD34Lu (from human
normal lung). MTS reduction rate (see Fig. 1 as an example) and LDH release were then measured
after 24 h to obtain EC50 values (the dose of peptide leading to 50% effect). Among all K-containing
peptides, only di-substituted K5K6 showed a signiﬁcantly reduced cytocidal effect against all cell
models (range: 50–60% inhibition) (Fig. 2).1.3. Modulation of trichogin eukaryotic cytotoxicity by replacing U with L
The cytotoxicity of native trichogin is weakly affected by replacing U1 with L (Fig. 3). The
importance of a stable helical structure for the bioactivity of trichogin was further conﬁrmed by the
reduced cell toxicity (50–70% inhibition) of L4 [7] and L1L4L8 (no helicogenic U residues in the
sequence) analogs. L4 was also found to be more toxic to HeLa cells than native trichogin. PI/Annexin
V labeling experiments (Fig. 4) conﬁrmed that L1 was as effective as trichogin in killing HeLa cells.1.4. Modulation of K-substitued trichogins by L and U further substitution
Cytotoxicity assays were performed on the K-containing analogs L1K2, L1K9, K5U6, K2K5K9U6
(Fig. 5). In most cases the cytotoxic effect against all the tested cells was not signiﬁcantly different
from that of the corresponding analogs K2, K5, K9 and K2K5K9, with the only exceptions of K5U6 and
K2K5K9U6, which showed an increased cytotoxicity. In agreement with MTS/LDH data, K5U6 was
signiﬁcantly more effective in killing HeLa cells as compared to either trichogin or K5. K5U6 induced
predominantly a late apoptotic phenotype but also signiﬁcant necrosis (Fig. 6).1.5. Hemolytic activity of trichogin analogs
We found that trichogin is weakly hemolytic and that U-to-L substitutions did not change the
hemolytic effect (Fig. 7). All K-containing analogs induced strong hemolysis (30–100%).0 5 10 15 20
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Fig. 1. Cytotoxicity on human cells of trichogin and its analogs with G to K modiﬁcations. HeLa and HL60 cells were incubated
for 24 h with the peptides at different concentrations and subjected to MTS assay. The values, expressed as percentage of
control, are the mean7SD of three experiments run in duplicate. S. epidermidis: Staphylococcus epidermidis.
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Fig. 2. Cytotoxicity on human cells of trichogin and it analogs with G to K modiﬁcations. Cells treated with increasing doses of
the peptides were subjected to MTS assay (A) or LDH assay (B). EC50 values of the cells treated with the peptides for 24 h, based
on MTS and LDH assays, are the mean of four experiments run in duplicate7SD. *po0.05 with respect to trichogin treated
cells. § Indicates data from [6] for comparison.
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2.1. Peptide synthesis and characterization
The sequences of the trichogin analogs investigated are listed in Table 1. The newly synthesized
peptides were prepared by solid-phase procedures, according to published protocols [9,10]. After
HPLC puriﬁcation, their purity was 496%. The peptides were characterized by means of HPLC and
mass spectrometry, as reported in Table 1.
2.2. Bacterial strains and antibacterial activity
E. coli ATCC 25922, the methicillin-resistant strain of S. aureus, ATCC BAA-44, P. aeruginosa ATCC
25668 and S. epidermidis ATCC 700565 was a kind gift of Prof. Elena Reddi (Dept. of Biology, University
of Padova, Italy). Cultures were maintained in Luria Bertani (LB) agar. MICs (Minimal inhibitory
concentrations) of the peptides were determined using the broth microdilution method. Two-fold
serial dilutions of each peptide, from 1 to 64 μM, were prepared in LB and 50 μl per well were
arranged in sterile 96-well plates (Falcon). Then, an aliquot of bacterial cell suspension was added to
each well, at a ﬁnal concentration of 5105 CFU/ml. After incubation for 24 h at 37 °C, the inhibition
of bacterial growth was assessed and the MIC endpoint was deﬁned as the lowest concentration of
the antimicrobial peptide that completely inhibited bacterial growth.
2.3. Cell isolation and culture
HeLa, A431 and CCD34-Lu cells were maintained in DMEM medium (Gibco), A549 in F12 medium
(Gibco) and HL60 in RPMI medium (Gibco), supplemented with 10% FCS (Euroclone) and antibiotics
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Fig. 3. Cytotoxicity on human cells of trichogin and its U to L analogs. Cells treated with increasing doses of the peptides were
subjected to MTS assay (A) or LDH assay (B). EC50 values of the cells treated with the peptides for 24 h, based on MTS and LDH
assays, are the mean of four experiments run in duplicate7SD. § Indicates data from [6] for comparison.
R. Tavano et al. / Data in Brief 6 (2016) 359–367364(penicillin and streptomycin, 100 U/ml, Invitrogen) at 37 °C in a humidiﬁed atmosphere containing 5%
(v/v) CO2; cells were split every 2–3 days. Human monocytes, polymorphonuclear leukocytes (PMNs)
and lymphocytes were puriﬁed from buffy coats of healthy donors, kindly provided by the Centro
Immunotrasfusionale, Hospital of Padova. Brieﬂy, for monocyte puriﬁcation, peripheral blood
mononuclear cells (PBMC) were isolated from buffy coats of healthy donors by density gradient
centrifugation on Ficoll-Paque Plus (GE Health care), which density is optimized for the isolation of
mononuclear cells. Separate monocyte and T-cell fractions were obtained from PBMCs by Percoll
density gradient centrifugation (GE Health care); residual lymphocytes were removed by incubation
in 2% fetal calf serum (FCS) RPMI at 37 °C and subsequently washed to eliminate non adherent cells.
Unless otherwise speciﬁed, cells were kept at 37 °C in a humidiﬁed atmosphere containing 5% (v/v)
CO2 in RPMI-1640 supplemented with 10% FCS. For PMNs puriﬁcation, the pellet of cells obtained
after the centrifugation on Ficoll gradient was subjected to dextran erythrocytes precipitation; resi-
dual erythrocytes were removed by hypotonic lysis in 155 mM NH4Cl, 10 mM KHCO3, and 100 mM
Na2EDTA at pH 7.4 and cells were cultured in RPMI medium, supplemented with 10% FCS. For lym-
phocytes preparation, buffy coats were incubated with 50 μl/ml of Rosette Seps Human T Cell
Enrichment Cocktail (StemCell Technologies). Blood was then centrifuged over a Ficoll gradient and
cells were cultured in RPMI medium, supplemented with 10% FCS.
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Fig. 4. Induction of necrosis (PIþ/V), apoptosis (PI/Vþ) or late apoptosis (PIþ/Vþ) in HeLa cells treated with U to L analogs
of trichogin. Cells treated as described in Fig. 3 were stained with Annexin-V-Fluorescein isothiocyanate (FITC) and Propidium
iodide (PI), and subjected to FACS analysis. Bars are the percentage of viable (PI/V), necrotic (PIþ/V), apoptotic (PI/Vþ)
and late apoptotic (PIþ/Vþ) cells from a representative experiment out of three. § Indicates data from [6] for comparison.
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Twenty-four hours before the experiment, A431, HeLa, A549 and CC34-Lu cells were detached bymeans
of trypsin treatment (Gibco), counted and seeded onto a 96 wells/plate (8103 cells/well, Falcon). After
puriﬁcation, monocytes were seeded onto a 96 wells/plate (2106/well) and left to adhere to the plastic;
then cells were immediately treated with stimuli. PMNs and lymphocytes (2106 cells/well) and HL60
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Fig. 6. Induction of necrosis (PIþ/V), apoptosis (PI/Vþ) or late apoptosis (PIþ/Vþ) in HeLa cells treated with K5U6 analog of
trichogin. Cells treated as described in Fig. 3 were stained with Annexin-V-FITC and Propidium iodide, and subjected to FACS
analysis. Bars are the percentage of viable (PI/V), necrotic (PIþ/V), apoptotic (PI/Vþ) and late apoptotic (PIþ/Vþ) cells
from a representative experiment out of three. § Indicates data from [6] for comparison.
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Fig. 7. Hemolytic activity of trichogin and its analogs. Erythrocytes were treated for 24 h with different concentration of
peptides, centrifuged and hemoglobin release was measured spectrophotometrically. Hemolysis is expressed as percentage
relative to positive control (erythrocytes treated with distilled water). § Indicates data from [6] for comparison.
R. Tavano et al. / Data in Brief 6 (2016) 359–367366cells (40103) were seeded onto cell plates and subsequently treated. Different peptides were diluted in
culture medium (from 20 μM to 1 μM) and added to the cells. As a positive control cells were treated with
medium without stimuli. Twenty-four hours after treatment, the cell supernatant was collected for sub-
sequent assay (LDH assay) and cells were tested using a CellTiter 96s AQueous One Solution Reagent
(Promega). Plates were read with an ELISA reader (Amersham Biosciences) at 492 nm. Data were expressed
as % of absorbance value compared to untreated cells (assumed as 100% viable). Alternatively, the EC50 (the
concentration of drug where 50% of cells died) was calculated for each peptide and each kind of tested cell.
R. Tavano et al. / Data in Brief 6 (2016) 359–367 3672.5. LDH assay
50 μl of the cell supernatant was tested with a CytoTox 96s Non-Radioactive Cytotoxicity Assay kit
(Promega). EC50 (the concentration of drug that induced the lysis of 50% of the total cell number) was
calculated for each peptide and each kind of tested cell.
2.6. Propidium iodide and Annexin V assay
HeLa cells were seeded on 24-wells plastic trays (Falcon) the day before the experiment, while HL60
were used directly. Cells were treated for 18 h with different trichogin analogs (up to 20 μM); then they
were washed with PBS, detached with trypsin (in the case of HeLa cells), centrifuged at 200g for 5 min,
suspended in 50 μl of incubation buffer and incubated for 15 min at 37 °C with 2 μl of Annexin-V-Fluos
(Roche). Cells were ﬁnally diluted in 250 μl of the incubation buffer and 15 μl of Propidium Iodide (Sigma)
were added to each sample just before the acquisitionwith FACSCantos (Beckton Dickinson). Percentage of
healthy (Annexin V/PI), apoptotic (Annexin Vþ/PI), oncotic (Annexin V/PIþ) and late apoptotic/
abortive oncotic (Annexin Vþ/PIþ) cells of the total (106 cells) was calculated using FACSDiva Software.Acknowledgments
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